Roche’s vision-loss drug Vabysmo gets EU nod

by user


Roche Holding AG said Monday that its vision-loss treatment Vabysmo has been approved in the European Union after successful phase-3 study data.

Vabysmo (faricimab) is a treatment for age-related macular degeneration and visual impairment due to diabetic macular edema, two conditions linked to vision loss, the Swiss pharmaceutical company
ROG,
-0.46%

said.

The approval from the European Commission–the EU’s executive arm–comes after four phase-3 studies showing vision gains and anatomical improvements in patients given the drug, Roche said.

The treatment will now be available in the bloc, adding to approvals in the U.S., the U.K. and Japan, Roche said. Submissions to other regulatory bodies continue, the company said.

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby



Source link

Related Posts

Leave a Review

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy